Cell and gene therapy reimbursement rate
STO-REC-STAT7J64CQT3 Research
42%
European Union · April 2023
Cell and gene therapy reimbursement rate in the European Union stood at 42% in April 2023 (IQVIA).
- Publisher
- IQVIA
- Authority tier
- T3 Research
- Locator
- Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.
Verbatim extraction verified: The figure 42% is directly attested in the quoted passage (Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X
- MLA
- IQVIA Institute. "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios." 2023, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X.
- Chicago
- IQVIA Institute. "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios." 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X.
- BibTeX
- @misc{iqvia2023cellt5kh2x, author = {{IQVIA Institute}}, title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios}, year = {2023}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- IQVIA Institute · homepage ↗
- Authority tier
- Tier 3 · Industry & Research
- Report
- Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
- Type
- Press release
- Published
- —
- Locator
- Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Archival URI
- /stat/stat_7J64CQDPE38R0DC4ACBET5KH2X